Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must agree to use appropriate birth control throughout the study~* Must have a diagnosis of CSU for at least 6 months~* Must have CSU symptoms for at least 8 consecutive weeks despite taking anti-histamines~* Must agree to take an anti-histamine every day during the trial~* Must be willing to enter information about symptoms in an electronic diary twice a day~Exclusion Criteria:~* Must not have a cause, other than CSU, for itching, hives, and/or angioedema (swelling beneath the skin)~* Must not have a current or recent active infection requiring antibiotics~* Must not have a history of anaphylaxis (severe, life threatening allergic reaction)~* Must not have asthma requiring medications other than short acting beta agonists (albuterol, etc.)~* Must not have received prior treatment with omalizumab, ligelizumab, or other experimental biologic for CSU

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY3454738 (Type: EXPERIMENTAL): 500 milligram (mg) LY3454738 administered intravenously (IV).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).